This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

Peru

  1. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included a feasibility and acceptability study with national stakeholders and healthcare providers in Ghana, Kenya, Malawi, Peru, Senegal, and Sri Lanka to assess their preferences for different hypothetical rotavirus vaccine options. These briefs provide an overview of the results in each of the study countries.
    Published: June 2022
    Type: Resource Page
  2. Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included: targeted analyses on the ideal age group for iNGRVs and potential future combination vaccine options, impact and cost effectiveness analyses, a feasibility and acceptability study with national stakeholders and healthcare providers in six countries, and a demand forecast. This brief provides a comprehensive summary of the results.
    Published: June 2022
    Type: Resource Page
  3. New evidence shows single-dose HPV vaccination is highly effective
    Published: April 2022
    Type: Article
  4. The Partnership for Vivax Elimination (PAVE) will support endemic countries in achieving their Plasmodium vivax (P. vivax) malaria elimination goals.PAVE will advance the development of quality-assured, child-friendly treatments for relapse prevention, and generate and consolidate evidence to support malaria-endemic countries in developing and implementing new strategies to eliminate P. vivax malaria.
    Published: July 2021
    Type: Press Release
  5. Together with over 400 external stakeholders from across 50 countries, PATH has crafted a new institutional strategy that responds to the current crises we face as a global community, to the needs and priorities of our local partners, and to the resounding calls for the continued transformation of our sector. To bring our new strategy to life for our external partners, we’ve developed a strategy brochure. The brochure explains why PATH exists (our mission), what we will do (our priorities) and, perhaps most importantly, how we will do it (our change strategies).
    Published: June 2021
    Type: Resource Page
  6. PATH is a leader in adapting health innovations with and for women across systems, populations, and geographies. This brief outlines PATH's vision, approach, and areas of expertise in Sexual and Reproductive Health.
    Published: January 2021
    Type: Resource Page
  7. PATH has partnered with volunteers, midwives, and doctors in Peru to develop a holistic approach for breast cancer detection and treatment.
    Published: October 2020
    Type: Article
  8. Experts and policymakers met to review research and plan for the pilot introduction of a new treatment protocol for P. vivax malaria in the Americas, against the backdrop of the COVID-19 pandemic.
    Published: October 2020
    Type: Press Release
  9. This brief summarizes the experience and capabilities of the PATH HPV Vaccine Team. For decades, PATH has been at the forefront of evidence-based strategies from HPV vaccine research and delivery to cervical cancer screening and treatment to ensure we best meet the needs and realities of these countries for the greatest health impact.
    Published: June 2020
    Type: Resource Page
  10. This brief summarizes the experience and capabilities of the PATH Cervical Cancer Team. For decades, PATH has been at the forefront of evidence-based strategies from HPV vaccine research and delivery to cervical cancer screening and treatment to ensure we best meet the needs and realities of these countries for the greatest health impact.
    Published: June 2020
    Type: Resource Page
Load more